Acanthosis Nigricans

Acanthosis nigricans (AN) is a skin reaction pattern characterized by symmetric, velvety, hyperpigmented, and thickened plaques, classically affecting the posterior and lateral neck and the axillae, and often extending to the groin and other flexures (antecubital and popliteal fossae, umbilicus, inframammary folds).^[1] Texture, not just colour, defines it: affected skin feels thickened and velvety on palpation, often with a fine, papillomatous surface, and skin tags frequently develop within or at the edge of the plaques.^[2]

The single most important teaching point for this condition is that acanthosis nigricans has no direct topical or systemic cure of its own — it is a cutaneous marker of an underlying process, not a primary skin disease. Correct management means identifying and treating whatever is driving it, not reflexively reaching for a cream. By far the most common driver is obesity-associated insulin resistance, where AN functions as a visible, low-cost flag for undiagnosed prediabetes or type 2 diabetes and should prompt real metabolic screening — arguably the single highest-value action a pharmacist can take on recognizing it.^[3][4] A minority of cases are medication-induced, and a rare but critical minority are paraneoplastic (malignant AN), with a distinct presentation that functions as a genuine cancer-screening trigger.^[1] Purely cosmetic topical options exist for patients bothered by residual pigmentation once the underlying cause has been identified and addressed, but these are adjunctive, not the primary intervention, and should never substitute for the metabolic or medication work-up.^[5]

• Obesity/overweight — the single strongest risk factor; AN prevalence rises steeply with BMI.
• Insulin resistance, prediabetes, and type 2 diabetes — AN is one of the few physical exam findings that reliably flags underlying insulin resistance before it is otherwise diagnosed.^[4]
• Polycystic ovary syndrome.
• Family history of AN, type 2 diabetes, or insulin resistance.
• Black, Hispanic, Indigenous, and South/East Asian populations are disproportionately affected at a given body weight, and AN is frequently under-recognized or dismissed as a normal skin-tone variant in patients with darker skin rather than assessed as a clinical finding — see Special Populations.^[2]
• Childhood and adolescent obesity — AN is increasingly seen in children and adolescents in step with rising pediatric obesity rates, and should prompt the same metabolic screening as in an adult.
• Use of a medication associated with AN (see Drug Tables).
• Other endocrinopathies: Cushing syndrome, acromegaly, hypothyroidism, Addison disease.
• Older age combined with a new, rapidly progressive presentation and an otherwise low pretest probability of insulin resistance — a risk factor for the malignant form specifically, not the benign form.

Separately, refer for (non-urgent) dermatology assessment when the diagnosis is genuinely uncertain, when the distribution or texture doesn't cleanly fit AN, or when a biopsy is needed to distinguish AN from a mimicking condition (see Assessment & Diagnosis).

History

• Onset and rate of progression — gradual over months to years favours the benign form; rapid progression over weeks favours malignant AN.
• Full distribution, explicitly including whether the palms, soles, or oral/mucosal surfaces are involved.
• Personal or family history of obesity, type 2 diabetes, prediabetes, PCOS, or other insulin-resistance risk factors.
• Complete medication list, including any recently started agent (see Drug Tables).
• Unexplained weight loss, anorexia, or other systemic symptoms.
• Age — new AN in an older adult without the usual metabolic risk profile carries more weight toward malignancy than the same finding in a younger patient with obesity.

Examination

Confirm the velvety, thickened texture (not just hyperpigmentation) on palpation, document the full distribution, and specifically check the palms, soles, and oral mucosa — a typical benign-pattern exam does not involve these sites, so finding them changes the differential immediately.^[1]

Basic work-up for a typical (benign-pattern) presentation

AN itself is diagnosed clinically; biopsy is reserved for atypical presentations or genuine diagnostic uncertainty.^[2] For a gradual-onset presentation in a patient with obesity or another insulin-resistance risk factor, arrange fasting plasma glucose or A1c (or both, per local practice) and a lipid profile, and screen for PCOS features (menstrual irregularity, hirsutism, acne) where relevant — this work-up is the actual clinical purpose AN exists to trigger.^[4]

Differential diagnosis

• Identify and treat the specific underlying cause — this is the actual treatment target, not clearing the skin directly.
• In obesity/insulin-resistance-associated AN: achieve meaningful weight loss and improved glycemic control, and formally diagnose and manage any prediabetes or type 2 diabetes uncovered by screening.
• In medication-induced AN: discontinue or substitute the culprit agent where clinically appropriate, in consultation with the prescriber.
• In malignant AN: achieve prompt cancer diagnosis and treatment — skin improvement follows successful tumour treatment and is not pursued as an independent goal.
• Reduce flexural maceration, malodour, and the risk of secondary bacterial or fungal infection in affected skin folds.
• Only once the underlying cause is identified and being addressed: offer realistic, adjunctive cosmetic improvement in pigmentation/texture to patients who are bothered by appearance.

• Structured weight-management support (dietitian referral, physical activity counselling) — the single most effective non-drug intervention for obesity/insulin-resistance-associated AN; improvement in the skin itself typically lags well behind weight loss and glycemic improvement.
• Skin-fold hygiene: keep affected flexures clean and dry, favour breathable fabrics, and gently pat rather than vigorously rub the area to limit friction-related worsening.
• Address malodour or maceration promptly, since thickened, occluded flexural skin is prone to secondary bacterial or yeast overgrowth.
• Set realistic expectations from the first visit: even with the underlying cause fully addressed, pigmentation and texture often improve slowly, over months, and may only partially resolve — this is the expected course, not a treatment failure.
• Skin tags associated with AN can be removed for comfort or cosmetic reasons (cryotherapy or snip excision by a clinician) — this addresses the skin tag, not the AN itself.

Pregnancy

Breastfeeding

Data on topical retinoids in lactation are limited; given the purely cosmetic indication, it is reasonable to defer cosmetic topical therapy until breastfeeding has ended rather than accept an avoidable, unknown-risk exposure.

Pediatrics and adolescents

AN in a child or adolescent living with obesity is an important, and increasingly common, trigger for the same prediabetes/type 2 diabetes screening recommended in adults — do not dismiss it as a benign incidental finding at this age.^[4] Early-onset, unusually extensive AN — especially with a family history or coexisting skeletal/craniofacial features — should raise suspicion for a familial (FGFR3-associated) syndrome and prompt genetics referral rather than routine obesity counselling alone.^[2]

Skin of colour

AN is disproportionately common, and disproportionately under-recognized, in patients with darker skin tones — the velvety texture and thickening can be mistaken for a normal variant of skin pigmentation rather than assessed as a clinical finding warranting metabolic screening. Actively palpate and examine flexural skin in at-risk patients rather than relying on visual impression alone, and apply the same screening threshold regardless of skin tone.^[2]

What to monitor depends entirely on which bucket the patient is in.

1. Confirm the diagnosis is genuinely AN and not a mimicking condition (see Assessment & Diagnosis) — a persistent, unchanged plaque that never responds to any intervention should prompt reconsideration of confluent and reticulated papillomatosis, pseudo-acanthosis nigricans, or another differential rather than escalating AN-directed therapy further.
2. Confirm the presumed cause was actually addressed — was the metabolic work-up completed and acted on, was the culprit medication genuinely stopped (not just planned to be stopped), and has enough time passed (months, not weeks) for skin improvement to plausibly show?
3. If a clear driver was addressed adequately and the skin still hasn't improved after a reasonable interval, widen the differential — screen more broadly for an occult endocrinopathy, or, in a patient with the relevant risk profile (older age, disproportionate/rapid course, mucosal or palm/sole involvement), reconsider malignant AN even if it wasn't the leading concern initially.
4. If cosmetic topical therapy specifically was tried without adequate response after a full 3-6 month trial, consider combination cosmetic therapy or referral for a procedural option (e.g., fractional CO2 laser, chemical peel) — but continue to frame this as optional and adjunctive.
5. Persistent diagnostic uncertainty at any point warrants dermatology referral, including biopsy if not already performed.

• Reaching for a topical cream before working up the underlying cause — the cream is never the primary intervention.
• Assuming AN in an older adult is automatically the benign, obesity-related form without actively checking for the malignant-pattern red flags (rapid onset, palm/sole/mucosal involvement, disproportionate pruritus).
• Not screening a child or adolescent with new AN for prediabetes/type 2 diabetes because "they're too young."
• Dismissing AN in a patient with darker skin as a normal pigmentation variant rather than examining and assessing it as a clinical finding.
• Not reviewing the medication list for a culprit drug before assuming the AN must be obesity-related.
• Overpromising cosmetic outcomes — even successful cause-directed treatment often leaves residual pigmentation for a long period, and patients should be told this up front.
• Using systemic therapy purely for cosmetic skin clearing — the toxicity is never justified for this indication.
• Confusing AN with confluent and reticulated papillomatosis, which looks superficially similar but is a completely different condition, unrelated to insulin resistance and treated with minocycline rather than weight loss or metabolic therapy.

How to use this table: Doses are adult doses unless a separate pediatric line is given, and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Culprit medications (can cause or worsen AN)

A drug appearing here is not automatically a reason to stop it — review with the prescriber, weighing the drug's own indication against the AN it may be driving. Not an exhaustive list.

Cause-directed pharmacotherapy

Treats the underlying insulin resistance or paraneoplastic symptom, not the skin itself.

Cosmetic-only topical options

Offer only once the underlying cause has been identified and is being actively addressed; none of these agents treat the underlying condition, and response is gradual, often over several months, and frequently partial.

Not indicated for cosmetic AN clearing

Listed to state explicitly that these should not be used purely for cosmetic skin clearing, not as routine options.